You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創勝集團-B(06628.HK)治療實體瘤藥物臨牀試驗申請獲FDA批準
阿思達克 09-14 12:01
創勝集團-B(06628.HK)公佈,公司的同類首創,靶向Gremlin1且具有人源化單克隆抗體TST003的臨牀試驗申請獲美國食品藥品監督管理局(FDA)批準。 Gremlin1是一種在多種人類癌症,例如食管癌、胰腺癌、胃癌等的基質細胞中高度表達的調節蛋白,且與腫瘤形成有關聯,能促進癌細胞的增殖、遷移、侵襲和轉移。在臨牀前研究中,TST003在體外及體內均表現出顯着的抗腫瘤活性。TST003有望成爲一種新型癌症治療方法,可作爲單藥療法或與免疫檢查點抑制劑及或其他抗腫瘤藥物聯用。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account